课题基金 / 基金详情

Assay Development

Assay Development
检测开发
批准号:
8336974
负责人:
Eduard A. Sergienko
金额:
$263.13万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Eduard A. Sergienko的其他基金

相似基金

相关文献

中文摘要
翻译
单元1.化验方法的开发、适应和实施 单位1负责所有化验活动,以及高温超导后的鉴定,执行:(A) HTS和HCS的测定发展和适应,(B)通过确证对HITS的初步表征 化验和ECSO/ICSQ测定,(C)二次和正交化验和筛选,(D)类似物试验 和化学优化化合物,以及(E)HITS和优化的初步作用模式研究 化合物。第一单元开发和改装了36个初级HTS,从而超过了MLSCN的目标 由各种读数组成的检测,导致迄今进行了39次筛查活动。该股还 制定了27种二次/反分析方法,以支持MLSCN项目。此外,该单位还支持22次命中 使用41个剂量-反应分析的优化/合成孔径雷达项目,生成了24,000个IC50 10点曲线 重复和执行>20项行动模式研究。单元1被组织成两个子单元:子单元1A将 开发和实施所有HTS测试,而子单元1B负责开发和优化软件 针对HCS的算法。
英文摘要
UNIT 1. ASSAY DEVELOPMENT, ADAPTATION, AND IMPLEMENTATION Unit 1 is a responsible for all assay activities, as well as for post-HTS hit characterization, performing: (a) assay development and adaptation for HTS and HCS, (b) initial characterization of hits through confirmatory assays and ECso/ICsq determination, (c) secondary and orthogonal assays and screens, (d) testing of analogs and chemistry-optimized compounds, and (e) preliminary mode-of-action studies on hits and optimized compounds. Unit 1 surpassed the MLSCN goals with the development and adaptation of 36 primary HTS assays consisting of a variety of read-outs, resulting in 39 screening campaigns thus far. The Unit also developed 27 secondary/counter assays to support the MLSCN projects. Additionally, the Unit supported 22 hit optimization/SAR projects using 41 dose-response assays, generated >24,000 IC50 10-point curves in duplicate and performed >20 mode-of-action studies. Unit 1 is organized into two subunits: subunit 1A will develop and implement all HTS assays, while subunit 1B is responsible for developing and optimizing software algorithms for HCS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer
Assay Development
Assay Development
海外基金